Dual antiplatelet therapy in acute ischemic stroke: Does diabetes mellitus define a target population? [PDF]
Nedelcu S.
europepmc +1 more source
The performance of ASpirin-FREE therapy after successful percutaneous coronary intervention for acute coronary syndrome: the ASFREE prospective pilot study. [PDF]
Joo D, Jo S, Byoun JT, Cho JY, Yun KH.
europepmc +1 more source
In Hospital Assessment and Management of High Bleeding Risk in Patients with ST-Elevation Myocardial Infarction (STEMI). [PDF]
Kim S +8 more
europepmc +1 more source
Single-Site Experience in the ONSET-OFFSET Study Demonstrates Pharmacodynamic and Pharmacokinetic Advantages of Ticagrelor over Clopidogrel in Patients with Chronic Coronary Syndromes. [PDF]
Judge HM, Parker WAE, Storey RF.
europepmc +1 more source
Redefining Dual Antiplatelet Strategies After Acute Coronary Syndrome: Insights from Recent RCTs. [PDF]
He M +6 more
europepmc +1 more source
ATP-related purinergic signaling via P2Y12 contributes to airway epithelial barrier integrity. [PDF]
Tsuya K +9 more
europepmc +1 more source
Beyond Linear Risk: A U-Shaped Association Between Platelet Reactivity and Mortality in Coronary Artery Disease. [PDF]
Zhangelova S +11 more
europepmc +1 more source
TIA: transient brain ischemia but persistent damage. [PDF]
Zheng P, Shi FD, Shi K.
europepmc +1 more source
Oral P2Y<sub>12</sub> inhibitors only versus cangrelor in critically ill patients requiring percutaneous coronary interventions supported by microaxial flow pumps. [PDF]
Schaffner C +11 more
europepmc +1 more source
Intravenous cangrelor as rescue therapy for acute thrombosis in neuroendovascular procedures: illustrative cases. [PDF]
Sahin ME +4 more
europepmc +1 more source

